Printer Friendly

CYTRX CORPORATION AND RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER TO COLLABORATE IN TUMOR RESEARCH

 CYTRX CORPORATION AND RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER
 TO COLLABORATE IN TUMOR RESEARCH
 NORCROSS, Ga., Aug. 26 /PRNewswire/ -- CytRx Corporation (NASDAQ-NMS: CYTR) announced today a license agreement with Rush- Presbyterian-St. Luke's Medical Center in Chicago.
 The license applies to certain novel agents that will be developed for the treatment of multidrug resistant tumors. At the present time, cancer treatment is complicated by a resistance to drugs that develops in some tumors. This new technology offers the potential to minimize or inhibit the resistance and treat the tumors more effectively in combination with conventional cancer drugs.
 Jack J. Luchese, president and chief executive officer of CytRx, said: "We are pleased to work with such a fine institution in the area of tumor research. The development of these novel agents for multidrug resistance is compatible with our core technology and consistent with the company's strategy to develop significant high-value pharmaceutical agents."
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing pharmaceutical products intended for use in the treatment of vascular, immune system, and infectious diseases as well as burns. Hunter's TiterMax(R), an important immunoadjuvant for use by the basic research community, is currently on the market; and feed additives intended to enhance growth in food animals are under development through Vetlife, Inc., a wholly owned subsidiary.
 -0- 8/26/92
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR) CO: CytRx Corporation; Rush-Presbyterian-St. Luke's Medical Center ST: Georgia IN: MTC SU: LIC


EA-BN -- AT003 -- 3320 08/26/92 08:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 26, 1992
Words:258
Previous Article:REICHHOLD CHEMICALS, INC. NAMES GAITHER CHIEF OPERATING OFFICER
Next Article:NORSTAN ANNOUNCES RECORD FIRST QUARTER RESULTS
Topics:


Related Articles
CYTRX CORPORATION AND RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER TO COLLABORATE IN TUMOR RESEARCH
NEW DATA DEMONSTRATE THAT RHEOTHRX(R) MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
NEW DATA DEMONSTRATE THAT RHEOTHRX MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
CYTRX FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR MULTIPLE DRUG RESISTANT CANCER TREATMENT
Vertex Pharmaceuticals Incorporated Expands Clinical Group.
United Therapeutics and the Rush Medical Center Commence Patient Enrollment in Phase 3 Trial of Beraprost for Moderate Pulmonary Hypertension.
Study Results On The Use of Celgene's Thalomid(R) (Thalidomide) As Treatment For Myelodysplastic Syndromes.
Phase II Hepatitis C Trial Initiated by Ribozyme Pharmaceuticals.
CytRx Corporation Sickle Cell Trial Results Published In The Journal of the American Medical Association.
/C O R R E C T I O N -- Eisai Inc. and Pfizer Inc/.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters